The techniques of the ribzi DNA causes a qualitative shift in the treatment of immune diseases
Dubai, February 12 / WAM / Daniel Gates, the founding partner and CEO of Myeloid Therapeutics, confirmed that the techniques of adjusting genome and regulating the expression of proteins using RNA (RNA) is a qualitative shift in developing innovative treatments targeting immune system diseases.
Gates said – in a statement to Emirates News Agency “WAM” on the sidelines of his participation in the second day of the World Government Summit 2025 – that these innovations provide unprecedented opportunities to treat genetic and immune diseases, with a focus on reducing the costs of treatments.
He pointed to the important role of artificial intelligence in accelerating the development and manufacture of medicines, explaining that its use in discovering new drugs requires more accurate data about human biology.
He revealed the cooperation of his company with the Australian government to support the development of ribosia DNA technologies and build local environmental systems, stressing that these partnerships enhance innovation and enable societies to face health challenges.
Gates stressed that international cooperation and the exchange of medical data are an essential element to accelerate the pace of innovation in the treatment of rare and incurable diseases, calling for the benefit of the Coffeted-19 pandemic lessons to develop more flexible organizational frameworks.
- For more: Follow Khaleejion 24 Arabic, Khaleejion 24 English, Khaleejion 24 Live, and for social media follow us on Facebook and Twitter
